{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:52:03Z","timestamp":1793656323427,"version":"4.5.1"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"37","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Oteseconazole was approved by the US FDA in April 2022. It is the first approved\nselective and orally bioavailable CYP51 inhibitor for the treatment of patients with\nrecurrent Vulvovaginal candidiasis. Herein, we describe its dosage, administration, chemical\nstructure, physical properties, synthesis, mechanism of action, and pharmacokinetics.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230220130024","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T10:56:54Z","timestamp":1676890614000},"page":"4170-4175","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oteseconazole: First Approved Orally Bioavailable and Selective\nCYP51 Inhibitor for the Treatment of Patients with Recurrent\nVulvovaginal Candidiasis"],"prefix":"10.2174","volume":"30","author":[{"given":"Surya K.","family":"De","sequence":"first","affiliation":[{"name":"Conju-probe, San Diego, California, USA"},{"name":"Department of Chemistry, Bharath University, Chennai, Tamil\nNadu, 600126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0140-6736(07)60917-9","volume":"369","author":"Sobel J.D.","year":"2007","unstructured":"Sobel J.D.; Vulvovaginal candidosis. Lancet 2007,369(9577),1961-1971","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fmicb.2019.00691","volume":"10","author":"Zhang J.","year":"2019","unstructured":"Zhang J.; Li L.; Lv Q.; Yan L.; Wang Y.; Jiang Y.; The fungal CYP51s: Their functions, structures, related drug resistance, and inhibitors. Front Microbiol 2019,10,691","journal-title":"Front Microbiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/21505594.2016.1257457","volume":"8","author":"Chang Y.L.","year":"2017","unstructured":"Chang Y.L.; Yu S.J.; Heitman J.; Wellington M.; Chen Y.L.; New facets of antifungal therapy. Virulence 2017,8(2),222-236","journal-title":"Virulence"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6728","DOI":"10.1074\/jbc.M117.778308","volume":"292","author":"Hargrove T.Y.","year":"2017","unstructured":"Hargrove T.Y.; Friggeri L.; Wawrzak Z.; Qi A.; Hoekstra W.J.; Schotzinger R.J.; York J.D.; Guengerich F.P.; Lepesheva G.I.; Structural analyses of Candida albicans sterol 14\u03b1-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J Biol Chem 2017,292(16),6728-6743","journal-title":"J Biol Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","volume":"73","author":"Brand S.R.","year":"2021","unstructured":"Brand S.R.; Sobel J.D.; Nyirjesy P.; Ghannoum M.A.; Schotzinger R.J.; Degenhardt T.P.; A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis 2021,73(7),e1518-e1524","journal-title":"Clin Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12281-021-00419-5","volume":"15","author":"Seiler G.T.","year":"2021","unstructured":"Seiler G.T.; Ostrosky-Zeichner L.; Investigational agents for the treatment of resistant yeasts and molds. Curr Fungal Infect Rep 2021,15(3),104-115","journal-title":"Curr Fungal Infect Rep"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/14656566.2021.1935868","volume":"22","author":"Stewart A.G.","year":"2021","unstructured":"Stewart A.G.; Paterson D.L.; How urgent is the need for new antifungals? Expert Opin Pharmacother 2021,22(14),1857-1870","journal-title":"Expert Opin Pharmacother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","volume":"16","author":"Sobel J.D.","year":"2021","unstructured":"Sobel J.D.; Nyirjesy P.; Oteseconazole: An advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol 2021,16(18),1453-1461","journal-title":"Future Microbiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/ijd.15999","volume":"61","author":"Gupta A.K.","year":"2021","unstructured":"Gupta A.K.; Talukder M.; Venkataraman M.; Review of the alternative therapies for onychomycosis and superficial fungal infections: Posaconazole, fosravuconazole, voriconazole, oteseconazole. Int J Dermatol 2021,61(12),1431-1441","journal-title":"Int J Dermatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.2147\/IDR.S274872","volume":"14","author":"Tortorano A.M.","year":"2021","unstructured":"Tortorano A.M.; Prigitano A.; Morroni G.; Brescini L.; Barchiesi F.; Candidemia: Evolution of drug resistance and novel therapeutic approaches. Infect Drug Resist 2021,14,5543-5553","journal-title":"Infect Drug Resist"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1093\/cid\/ciab1057","volume":"74","author":"Nyirjesy P.","year":"2022","unstructured":"Nyirjesy P.; Brookhart C.; Lazenby G.; Schwebke J.; Sobel J.D.; Vulvovaginal candidiasis: A review of the evidence for the 2021 centers for disease control and prevention of sexually transmitted infections treatment guidelines. Clin Infect Dis 2022,74(Suppl. 2),S162-S168","journal-title":"Clin Infect Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","volume":"31","author":"Hoenigl M.","year":"2022","unstructured":"Hoenigl M.; Sprute R.; Arastehfar A.; Perfect J.R.; Lass-Fl\u00f6rl C.; Bellmann R.; Prattes J.; Thompson G.R.; Wiederhold N.P.; Al Obaidi M.M.; Willinger B.; Arendrup M.C.; Koehler P.; Oliverio M.; Egger M.; Schwartz I.S.; Cornely O.A.; Pappas P.G.; Krause R.; Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs 2022,31(8),795-812","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11908-022-00782-5","volume":"24","author":"Logan A.","year":"2022","unstructured":"Logan A.; Wolfe A.; Williamson J.C.; Antifungal resistance and the role of new therapeutic agents. Curr Infect Dis Rep 2022,24(9),105-116","journal-title":"Curr Infect Dis Rep"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"880.e1","DOI":"10.1016\/j.ajog.2022.07.023","volume":"227","author":"Martens M.G.","year":"2022","unstructured":"Martens M.G.; Maximos B.; Degenhardt T.; Person K.; Curelop S.; Ghannoum M.; Flynt A.; Brand S.R.; Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. Am J Obstet Gynecol 2022,227(6),880.e1-880.e11","journal-title":"Am J Obstet Gynecol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/jof8080857","volume":"8","author":"Wiederhold N.P.","year":"2022","unstructured":"Wiederhold N.P.; Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents. J Fungi 2022,8(8),857","journal-title":"J Fungi"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","volume":"24","author":"Hoekstra W.J.","year":"2014","unstructured":"Hoekstra W.J.; Garvey E.P.; Moore W.R.; Rafferty S.W.; Yates C.M.; Schotzinger R.J.; Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett 2014,24(15),3455-3458","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=17","author":"Hoekstra W.J.","year":"2020","unstructured":"Hoekstra W.J.; Yates C.M.; Mycovia Pharmaceuticals Inc, Antifungal compound process. 2020"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1128\/AAC.00349-16","volume":"60","author":"Warrilow A.G.S.","year":"2016","unstructured":"Warrilow A.G.S.; Parker J.E.; Price C.L.; Nes W.D.; Garvey E.P.; Hoekstra W.J.; Schotzinger R.J.; Kelly D.E.; Kelly S.L.; The investigational drug VT-1129 is a highly potent inhibitor of cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob Agents Chemother 2016,60(8),4530-4538","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"759408","DOI":"10.3389\/fcimb.2021.759408","volume":"11","author":"Murphy S.E.","year":"2021","unstructured":"Murphy S.E.; Bicanic T.; Drug resistance and novel therapeutic approaches in invasive candidiasis. Front Cell Infect Microbiol 2021,11,759408","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.tips.2022.10.004","volume":"44","author":"Vanreppelen G.","year":"2023","unstructured":"Vanreppelen G.; Nysten J.; Baldewijns S.; Sillen M.; Donders G.; Van Dijck P.; Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis. Trends Pharmacol Sci 2023,44(1),64-65","journal-title":"Trends Pharmacol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e01304","DOI":"10.1128\/AAC.01304-19","volume":"63","author":"Nishimoto A.T.","year":"2019","unstructured":"Nishimoto A.T.; Whaley S.G.; Wiederhold N.P.; Zhang Q.; Yates C.M.; Hoekstra W.J.; Schotzinger R.J.; Garvey E.P.; Rogers P.D.; Impact of the major candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob Agents Chemother 2019,63(10),e01304-e01319","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/jac\/dkx352","volume":"73","author":"Break T.J.","year":"2018","unstructured":"Break T.J.; Desai J.V.; Natarajan M.; Ferre E.M.N.; Henderson C.; Zelazny A.M.; Siebenlist U.; Hoekstra W.J.; Schotzinger R.J.; Garvey E.P.; Lionakis M.S.; VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans. J Antimicrob Chemother 2018,73(1),151-155","journal-title":"J Antimicrob Chemother"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230220130024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213817\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230220130024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:03:53Z","timestamp":1693685033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213817\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230220130024","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}